[1]李凯,赵国庆,李亮.舒更葡糖的应用进展[J].麻醉安全与质控,2019,3(04):236-239.[doi:10.3969/j.issn.2096-2681.2019.04.013]
 LI Kai,ZHAO Guoqing,LI Liang.Progress in clinical application of sugammadex[J].Perioperative Safety and Quality Assuance,2019,3(04):236-239.[doi:10.3969/j.issn.2096-2681.2019.04.013]
点击复制

舒更葡糖的应用进展()
分享到:

《麻醉安全与质控》[ISSN:2096-1245/CN:CN 61-1505/R]

卷:
3
期数:
2019年04期
页码:
236-239
栏目:
综述
出版日期:
2019-08-15

文章信息/Info

Title:
Progress in clinical application of sugammadex
作者:
李凯 赵国庆 李亮
吉林大学中日联谊医院麻醉科, 吉林 长春 130021
Author(s):
LI Kai ZHAO Guoqing LI Liang
Department of Anesthesiology, China-Japan Union Hospital of Jilin University, Changchuan 130021, China
关键词:
SUG 肌松药拮抗药
Keywords:
SUG muscle relaxant antagonist
DOI:
10.3969/j.issn.2096-2681.2019.04.013
摘要:
舒更葡糖(SUG)是一种新型非去极化肌松药拮抗药, 对罗库溴铵和维库溴铵等甾体类非去极化肌松药物具有特异性的快速的拮抗作用, 其效果优于乙酰胆碱酯酶抑制剂。 可用于合并脏器功能障碍、 重症肌无力、 困难气道以及特殊人群等患者。本文对其作用机制、 药代动力学特点、 临床应用及安全性和不良反应进行综述。
Abstract:
Sugammadex (SUG) is a new type of non-depolarizing muscle relaxant antagonist, which has a specific and rapid antagonistic effect on steroidal non-depolarizing muscle relaxants such as rocuronium and vecuronium, and its effect is better than that of acetylcholinesterase inhibitors. It can be used in patients with organ dysfunction, myasthenia gravis, difficult airway or special groups of patients. The mechanism, pharmacokinetic characteristics, clinical application, safety and adverse reactions of SUG are reviewed in this paper.

参考文献/References:

[1] BLOBNER M, ERIKSSON L I, SCHOLZ J, et al. Reversal of rocuroniuminduced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial[J]. Eur J Anaesthesiol, 2010, 27(10): 874-881.DOI: 10.1097/EJA.0b013e32833d56b7.
[2] HRISTOVSKA A M, DUCH P, ALLINGSTRUP M, et al. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults[J]. Cochrane Database Syst Rev, 2017, 8:CD012763. DOI: 10.1002/14651858.CD012763.
[3] AMAO R, ZORNOW M H, COWAN R M, et al. Use of sugammadex in patients with a history of pulmonary disease[J]. J Clin Anesth, 2012, 24(4): 289-297.DOI: 10.1016/j.jclinane.2011.09.006.
[4] DAHL V, PENDEVILLE P E, HOLLMANN M W, et al. Safety and efficacy of sugammadex for the reversal of rocuronium-in-duced neuromuscular blockade in cardiac patients undergoing noncardiac surgery[J]. Eur J Anaesthesiol, 2009, 26(10): 874-884.DOI: 10.1097/EJA.0b013e32832c605b.
[5] FUJITA A, ISHIBE N, YOSHIHARA T, et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver dysfunction undergoing hepatic surgery[J]. Acta Anaesthesiol Taiwan, 2014, 52(2): 54-58.DOI: 10.1016/j.aat.2014.04.007.
[6] STAALS L M, SNOECK M M, DRIESSEN J J, et al. Multicentre,parallel-group,comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure of normal renal function[J]. Br J Anaesth, 2008, 101(4): 492-497.DOI: 10.1093/bja/aen216.
[7] DUARTE N M D C, CAETANO A M M, NETO S D S C, et al. Sugammadex by ideal body weight versus 20% and 40% corrected weight in bariatric surgery-double-blind randomized clinical trial[J]. Rev Bras Anestesiol, 2018, 68(3): 219-224. DOI: 10.1016/j.bjan.2017.10.010.
[8] PATON L, GUPTA S, BLACOE D. Successful use of sugammadex in a‘can’t ventilate’ scenario[J]. Anaesthesia, 2013, 68(8): 861-864.DOI: 10.1111/anae.12338.
[9] VYMAZAL T, KRECMEROVA M, BICEK V, et al.Feasibility of full and rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients undergoing surgery: a series of 117 cases[J].Ther Clin Risk Manag, 2015, 11: 1593-1596.DOI: 10.2147/TCRM.S93009.
[10] WOLOSZCZUK-GEBICKA B, ZAWADZKA-GLOS L, LENARCZYK J, et al. Two cases of the “cannot ventilate,cannot intubate” scenario in children in view of recent recommendations[J]. Anaesthesiol Intensive Ther, 2014, 46(2): 88-91. DOI: 10.5603/ait.2014.0017.
[11] FRANZ A M, CHIEM J, MARTIN L D, et al. Case series of 331 cases of sugammadex compared to neostigmine in patients under 2 years of age[J].Paediatr Anaesth, 2019, 29(6): 591-596. DOI: 10.1111/pan.13643.
[12] YAZAR E, YILMAZ, BILGIN H, et al. A comparision of the effect of sugammadex on the recovery period and postoperative residual block in young elderly and middle-aged elderly patients[J]. Balkan Med J, 2016, 33(2): 181-187. DOI: 10.5152/balkanmedj.2016.16383.
[13] DE KAM P J, NOLTE H, GOOD S, et al. Sugammadex hypersensitivity and underlying mechanisms: a randomised study of healthy non-anaesthetised volunteers[J]. Br J Anaesth, 2018, 121(4): 758-767. DOI: 10.1016/j.bja.2018.05.057.
[14] MIN K C, WOO T, ASSAID C, et al. Incidence of hypersensitivity and anaphylaxis with sugammadex[J]. J Clin Anesth, 2018, 47(3): 67-73. DOI: 10.1016/j.jclinane.2018.03.018.
[15] MOON Y J, KIM S H, KIM J W, et al. Comparison of postoperative coagulation profiles and outcome for sugammadex versus pyridostigmine in 992 living donors after living-donor hepatectomy[J/OL]. Medicine(Baltimore), 2018, 97(11): e0129. DOI: 10.1097/MD.0000000000010129.

备注/Memo

备注/Memo:
收稿日期: 2019-04-05; 接受日期: 2019-06-05
基金项目: 吴阶平医学基金会(320.6750.18187);吉林省发改委项目(2018C020)
作者简介: 李凯, 主治医师, 博士, E-mail: likai82@126.com
通信作者: 李亮, E-mail: 1035179890@qq.com
更新日期/Last Update: 2019-08-15